Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma

被引：1

作者：

Weiss, Jonathan M. ^{[1
]}

Phillips, Tycel J. ^{[2
]}

机构：

[1] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[2] City Of Hope, Dept Hematol & Hematopoiet Cell Transplantat, Div Lymphoma, Comprehens Canc Ctr, Duarte, CA 91010 USA

来源：

CANCERS | 2024年 / 16卷 / 09期

关键词：

NHL; BsABs; bispecifics; DLBCL; FL; MCL; treatment; management; RITUXIMAB PLUS LENALIDOMIDE; FOLLICULAR LYMPHOMA; 1ST-LINE TREATMENT; SINGLE-ARM; OPEN-LABEL; SUBCUTANEOUS EPCORITAMAB; MULTICENTER; SURVIVAL; BENDAMUSTINE; CHOP;

D O I：

10.3390/cancers16091724

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Bispecific antibodies are a novel type of immune-based therapy used to treat patients with non-Hodgkin's lymphoma. This review article will help define the current treatment landscape of non-Hodgkin's lymphoma and detail ways in which bispecific antibodies fit in the current management paradigm, with special attention paid to diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.Abstract B-cell non-Hodgkin's lymphoma (NHL) refers to a heterogenous group of diseases, all of which have a wide range of treatment strategies and patient outcomes. There have been multiple novel, immune-based therapies approved in NHL in the last decade, including bispecific antibodies (BsAbs) and chimeric antigen receptor therapy (CAR-T). With a host of new therapies, an important next step will be determining how these therapies should be sequenced in contemporary management strategies. This review seeks to offer a framework for the ways in which BsABs can be incorporated into the current management paradigm for NHL, with special attention paid to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

引用

页数：12

共 52 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2] Therapy Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access [J].

Ahmed, Nausheen ;

Shahzad, Moazzam ;

Shippey, Ernie ;

Bansal, Rajat ;

Mushtaq, Muhammad Umair ;

Mahmoudjafari, Zahra ;

Faisal, Muhammad Salman ;

Hoffmann, Marc ;

Abdallah, Al-Ola ;

Divine, Clint ;

Hamadani, Mehdi ;

McGuirk, Joseph ;

Shune, Leyla .

TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (07) :358-364

[3] Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011 [J].

Al-Hamadani, Mohammed ;

Habermann, Thomas M. ;

Cerhan, James R. ;

Macon, William R. ;

Maurer, Matthew J. ;

Go, Ronald S. .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (09) :790-795

[4] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) [J].

Ayyappan, Sabarish ;

Kim, Won Seog ;

Kim, Tae Min ;

Walewski, Jan ;

Cho, Seok-Goo ;

Jarque, Isidro ;

Iskierka-Jazdzewska, Elzbieta ;

Poon, Michelle ;

Oh, Sung Yong ;

Lim, Francesca Lorraine Wei Inng ;

Carpio, Cecilia ;

Tan, Tran-Der ;

Gutierrez, Antonio ;

Zhang, Huilai ;

Cao, Junning ;

Zhang, Mingzhi ;

Tessoulin, Benoit ;

Li, Jingjin ;

Ufkin, Melanie ;

Shariff, Saleem ;

Chi, Lei ;

Chaudhry, Aafia ;

Mohamed, Hesham ;

Ambati, Srikanth ;

Prince, H. Miles .

BLOOD, 2023, 142

[5]

Brody J, 2022, J CLIN ONCOL, V40

[6] Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance [J].

Brouwer-Visser, Jurriaan ;

Fiaschi, Nathalie ;

Deering, Raquel P. ;

Dhanik, Ankur ;

Cygan, Kamil J. ;

Zhang, Wen ;

Jeong, Se ;

Pourpe, Stephane ;

Boucher, Lauren ;

Hamon, Sara ;

Topp, Max S. ;

Bannerji, Rajat ;

Duell, Johannes ;

Advani, Ranjana ;

Flink, Dina M. ;

Chaudhry, Aafia ;

Sirulnik, Andres ;

Murphy, Andrew J. ;

Weinreich, David M. ;

Yancopoulos, George D. ;

Thurston, Gavin ;

Ambati, Srikanth R. ;

Jankovic, Vladimir .

BLOOD, 2020, 136

[7] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [J].

Brown, J. R. ;

Eichhorst, B. ;

Hillmen, P. ;

Jurczak, W. ;

Kazmierczak, M. ;

Lamanna, N. ;

O'Brien, S. M. ;

Tam, C. S. ;

Qiu, L. ;

Zhou, K. ;

Simkovic, M. ;

Mayer, J. ;

Gillespie-Twardy, A. ;

Ferrajoli, A. ;

Ganly, P. S. ;

Weinkove, R. ;

Grosicki, S. ;

Mital, A. ;

Robak, T. ;

Osterborg, A. ;

Yimer, H. A. ;

Salmi, T. ;

Wang, M. -D. -Y. ;

Fu, L. ;

Li, J. ;

Wu, K. ;

Cohen, A. ;

Shadman, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04) :319-332

[8] Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Primary Analysis of a Phase Ib/II Study [J].

Budde, L. Elizabeth ;

Olszewski, Adam J. ;

Assouline, Sarit ;

Lossos, Izidore S. ;

Diefenbach, Catherine ;

Kamdar, Manali ;

Ghosh, Nilanjan ;

Modi, Dipenkumar ;

Sabry, Waleed ;

Naik, Seema ;

Mehta, Amitkumar ;

Nakhoda, Shazia K. ;

Smith, Stephen D. ;

Dorritie, Kathleen ;

Jia, Ting ;

Pham, Song ;

Huw, Ling-Yuh ;

Wu, Hao ;

To, Iris ;

Wei, Michael C. ;

Chavez, Julio C. .

BLOOD, 2023, 142

[9] Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study [J].

Budde, Lihua E. ;

Sehn, Laurie H. ;

Matasar, Matthew ;

Schuster, Stephen J. ;

Assouline, Sarit ;

Giri, Pratyush ;

Kuruvilla, John ;

Canales, Miguel ;

Dietrich, Sascha ;

Fay, Keith ;

Ku, Matthew ;

Nastoupil, Loretta ;

Cheah, Chan Yoon ;

Wei, Michael C. ;

Yin, Shen ;

Li, Chi-Chung ;

Huang, Huang ;

Kwan, Antonia ;

Penuel, Elicia ;

Bartlett, Nancy L. .

LANCET ONCOLOGY, 2022, 23 (08) :1055-1065

[10] Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study [J].

Budde, Lihua E. ;

Assouline, Sarit ;

Sehn, Laurie H. ;

Schuster, Stephen J. ;

Yoon, Sung-Soo ;

Yoon, Dok Hyun ;

Matasar, Matthew J. ;

Bosch, Francesc ;

Kim, Won Seog ;

Nastoupil, Loretta J. ;

Flinn, Ian W. ;

Shadman, Mazyar ;

Diefenbach, Catherine ;

O'Hear, Carol ;

Huang, Huang ;

Kwan, Antonia ;

Li, Chi-Chung ;

Piccione, Emily C. ;

Wei, Michael C. ;

Yin, Shen ;

Bartlett, Nancy L. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) :481-+

← 1 2 3 4 5 6 →